The purpose of this feature is to heighten awareness of specifi c adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Admin- 
VIGABATRIN-INDUCED ENCEPHALOPATHY
A 10-month-old female who was diagnosed the month prior with infantile spasms presented with progressive lethargy, followed by a movement disorder and fi nally left hemiparesis. The child had been receiving vigabatrin (Sabril) 150 mg/kg/day and tetracosactide 0.75 mg on alternate days for the prior 14 days. An MRI scan revealed rapidly progressive signal changes within the basal ganglia, brainstem, and cerebellum compared to neuroimaging performed earlier, after the onset of her spasms. All additional neurometabolic investigations were eventually found to be normal. Treatment with vigabatrin was discontinued on day 22 of therapy. The patient started to make a dramatic recovery within 48 hours of vigabatrin discontinuation and went on to make a full neurological recovery.
In a review of 3 studies evaluating the use of vigabatrin and MRI results, the authors point out that MRI imaging abnormalities within the globus pallidus, thalamus, brainstem, and dentate nuclei are reported in up to 30% of patients with infantile spasms who receive vigabatrin. These abnormalities appear specifi c to children with infantile spasms, affect younger infants and children, are associated with a higher dosage of vigabatrin (>80 mg/kg/day), and are reversible after the discontinuation of vigabatrin treatment. The inconsistency is that these MRI abnormalities do not consistently correlate with the drowsiness, lethargy, tremor, and abnormal coordination reported in children and adults receiving vigabatrin.
The authors theorize that the potential mechanism of these MRI and clinical observations are largely unknown and may be due to age-specifi c or disease state-specifi c conditions. They warn that early recognition of these adverse effects is particularly important, because failure to recognize this condition would have led to palliative management of their patient. 
FIDAXOMICIN HYPERSENSITIVITY REACTIONS
Fidaxomicin (Difi cid) is a macrolide antibiotic that is indicated for the treatment of Clostridium diffi cile-associated diarrhea (CDAD). Fidaxomicin is minimally absorbed with maximal plasma concentrations of fi daxomicin and OP-1118 (primary metabolite) in the nanogram per mL range. Because fi daxomicin is minimally absorbed, systemic adverse reactions are not expected and may not be considered, especially in a patient receiving multiple concomitant medications.
In clinical trials with fi daxomicin, no specifi c concerns related to hypersensitivity reactions were identifi ed. However, after fi daxomicin's release, reports of hypersensitivity reactions were reported to the US Food and Drug Administration (FDA). Eleven cases of hypersensitivity reactions were reported to the FDA, and one case was reported in the literature. A history of macrolide allergy was documented in 3 of 12 cases.
In all the cases of fi daxomicin hypersensitivity reviewed, 6 patients reported facial, tongue, or throat swelling; 4 reported a diffuse rash; and 1 reported a burning sensation in the throat. A patient described in the literature had a purpuric rash on the lower extremities. The time to onset of the hypersensitivity reactions was between 1 and 7 hours after fi rst receiving fi daxomicin. Ten cases resolved after discontinuation of fi daxomicin; one patient continued fi daxomicin along with diphenhydramine and the itching and rash persisted and one patient had an unknown outcome. Two patients had a positive rechallenge with fi daxomicin.
The fi daxomicin labeling has been changed to refl ect the risk of hypersensitivity reactions. The warning in the labeling states that a history of macrolide allergy should be taken into consideration when initiating fi daxomicin, given that 3 of 12 patients reported a history of macrolide allergy. It is possible that the colonic infl ammation caused by C. diffi cile infection can increase the bioavailability of fi daxomicin. It has been hypothesized that in a predisposed patient, a minimal systemic exposure or even contact with infl amed mucosa could be suffi cient to cause an allergic reaction.
The authors from the Division of Anti-infective Products at the FDA warn that health care providers should be aware of the risk of hypersensitivity reactions with fi daxomicin. It is important to report these events to the FDA MedWatch program when they occur. 
VEMURAFENIB-INDUCED DRESS
A female in her 80s reported a 1-year history of a violet colored growth on her calf. A biopsy revealed a nodular melanoma and 2 suspect lymph nodes. The diagnosis of metastatic melanoma with V600E BRAF mutation was confi rmed and vemurafenib (Zelboraf) was initiated. The patient's past medical history included hypertension and chronic kidney disease. The patient began treatment with vemurafenib 960 mg twice daily. Three weeks later, she developed scattered pustules and generalized pink, pruritic papules coalescing into plaques on the face, trunk, and extremities with prominent facial edema.
On hospital admission, the patient complained of fevers, chills, and bone pain but was afebrile. However, 3 days prior, a low-grade fever of 37.3 o C (99.1 o F) was documented during an outpatient visit, and she was advised to begin antipyretic drugs. Her laboratory results revealed the following: WBC 12.4 x 10 3 / μL (normal value, 4.1-10.9 x 10 3 /μL), 26% eosinophils (normal value, 1%-3%), AST 107 IU/L (normal value, <35 IU/L), ALT 132 IU/L (normal value, 10-35 IU/L), and serum creatinine 3.3 mg/dL (normal value, female 0.6-1.2 mg/dL) with the patient's normal baseline creatinine of 1.8 mg/dL. The patient's medication history included metoprolol and hydrochlorothiazide, which she had been receiving for at least the last 9 months. Based on the patient's symptoms, a drug eruption was suspected and her vemurafenib treatment was discontinued.
A skin biopsy was performed, and the fi ndings supported the diagnosis of a drug reaction with eosinophilia and systemic symptoms (DRESS). Intra-Volume 49, May 2014 venous methylprednisolone was initiated followed by oral prednisone; over the subsequent 6 weeks, the patient experienced desquamation and resolution of her skin eruption and laboratory abnormalities.
The authors point out that DRESS is most commonly associated with the use of aromatic anticonvulsants. A defect in the detoxifi cation of certain drugs is thought to play a role in the development of DRESS, producing toxic metabolites that cause cellular injury and trigger an immune response. Recently, viruses such as human herpesvirus (HHV)-6, HHV-7, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) have been implicated in the development of DRESS. The patient was found to have an elevated HHV-6 IgG titer (1:160; normal <1:10), which indicates a possible viral reactivation. EBV DNA was also detected, whereas CMV and HHV-7 test results were negative. It is unclear whether these observations are a consequence or cause of the condition.
The authors want to emphasize that the occurrence of DRESS in association with vemurafenib therapy has not been reported. Clinicians should be aware of this possible complication in patients receiving vemurafenib. 
SEVERE ALKALOSIS AND HYPOKALEMIA WITH STANOZOLOL MISUSE
A 30-year-old man with a history of alcohol and cocaine misuse presented to the emergency department (ED) after a witnessed seizure. Upon arrival, the patient was incoherent, with a Glasgow Coma Scale score of 12/15, a blood pressure of 140/85 mm Hg, and a pulse of 75 bpm. The patient was globally weak on neurologic examination but with no focal defi cits, and a CT of his head was normal. The patient's arterial blood gas showed a pH of 7.7 (reference range, 7.34-7.45), PaCo 2 of 6.5 kPa (reference range, 4.4-5.9 kPa), and bicarbonate of 58.9 mEq/L (reference range, 22-26 mEq/L). Chem-7 results were a plasma potassium of 1.7 mEq/L (reference range, 3.5-5 mEq/L), sodium of 124 mEq/L (reference range, 135-147 mEq/L), corrected calcium of 8.6 mg/dL (reference range, 8.5-10.2 mg/dL), magnesium of 3 mg/dL (reference range, 1.8-3 mg/dL), creatinine of 1.83 mg/dL (reference range, male 0.8-1.4 mg/dL), and BUN 44 mg/dL (reference range, 7-20 mg/dL). A urine drug screen was negative for benzodiazepines, opioids, barbiturates, cannabinoids, and cocaine. Additional blood tests, including thyroid and liver function tests, amylase, glucose, acetaminophen, and salicylate levels were within normal limits.
The patient was treated with parenteral fl uid rehydration and potassium replacement. The clinical impression was syndrome of mineralocorticoid excess. The patient's plasma renin and aldosterone concentrations were within normal limits, implying an acute exposure to exogenous steroid. Over the next 48 hours, the patient's electrolyte imbalances and alkalosis were corrected, and his level of consciousness returned to normal. The patient was interviewed, and he revealed he had ingested 50 g of stanozolol (Winstrol), as a body-building supplement, during the week before his hospital admission. The patient denied any other concurrent medications or illicit substance use, including diuretics. He also denied a history of vomiting or diarrhea.
The authors point out that stanozolol is known to enhance glucocorticoid in vitro and potentially mineralocorticoid activity, which would account for the patient's electrolyte abnormalities. Typically the dose of stanozolol taken depends on the indication. In patients with hereditary angioedema, doses of 0.5 to 2 mg daily are utilized, whereas body builders and athletes may administer quantities ranging from 50 to 100 mg daily. Even at a 50 to 100 mg daily dose, stanozolol is thought to be safe and side effects are very rarely experienced. The patient admitted to having ingested a weekly dose 1,000 times greater than normally encountered.
Upon review of the patient's blood tests from prior admissions over previous years, it was noted that the patient demonstrated a trend toward hypokalemia. This might imply that he possesses an underlying renal tubular dysfunction that could increase his susceptibility to the mineralocorticoid effects of stanozolol. The patient was discharged from the hospital with an appointment to have follow-up tests to investigate possible renal tubular dysfunction. The patient did not attend his scheduled appointment and was lost to follow-up.
The authors conclude that stanozolol misuse can precipitate profound hypokalemia and metabolic alkalosis. Patients may present with reduced consciousness and therefore may be unable to provide a clear history of substance ingestion. This case is important, because stanozolol misuse is relatively common. Although stanozolol is considered relatively safe when utilized in standard doses, excessive dosing can lead to life-threatening complications. 
ISOTRETINOIN-ASSOCIATED LIP ABSCESS
A 15-year-old male with a 2-day history of a lower lip swelling was seen by his doctor. The boy's mother described a rapid onset of edema, erythema, and pain in the lower lip. The boy's condition was initially thought to be allergic angioedema, and corticosteroid therapy was initiated by his pediatrician. Corticosteroid therapy did not lead to a resolution of the lip edema. The patient was then initiated on cephalexin for a presumed infection. Despite 3 doses of cephalexin, the lip swelling continued to progress substantially. The patient was otherwise healthy with no fever or chills. The patient's medical history only included acne vulgaris, for which he was receiving isotretinoin.
The patient returned to his pediatrician and was found to be afebrile and normotensive, however his lower lip was extremely edematous and erythematous. Both sides of his lower lip were very tense and painful. The physician performed a needle aspiration of the lip, which returned frank purulence. The lips was incised and drained with the release of copious amounts of purulence. The abscess pocket extended the full length of the lip. Samples were sent for culture and the patient was admitted to the hospital for empiric intravenous ampicillin-sulbactam and vancomycin. The patient remained afebrile throughout his hospital stay with substantial improvement in lower lip edema, erythema, and pain. Cultures grew methicillin-resistant Staphylococcus aureus (MRSA) that was resistant to clindamycin. The patient was discharged with a prescription for trimethoprimsulfamethoxazole oral therapy.
The mucocutaneous effects of isotretinoin include xerostomia and lip swelling (cheilitis). Since these effects are common, the absence of mucocutaneous symptoms implies medication nonadherence. The fi ssuring and cracking of the lips with cheilitis leads to the breakdown of an important mucocutaneous barrier and can predispose patients to bacterial or viral infections. In addition to causing breakdown of mucosal barriers, isotretinoin also leads to increased colonization with S. aureus, which increases the incidence of folliculitis and furunculosis (boils).
The authors theorize that the use of isotretinoin leading to cheilitis, decreased mucocutaneous barriers, and staphylococcal colonization likely caused the severe lip abscess in the patient. In addition, both of the patient's parents were health care providers and presumably exposed the patient to carriage of MRSA. The authors hope to raise awareness of the development of severe lip abscesses related to isotretinoin use and to prevent delayed diagnosis of this serious complication of a commonly utilized acne treatment. 
ELTROMBOPAG-ASSOCIATED HYPERPIGMENTATION
A 69-year-old White female with refractory acute myelogenous leukemia (AML) was noted to have a graying of her skin. The patient had been receiving eltrombopag (Promacta) 300 mg/day as part of a clinical trial for 3 months. The patient's husband and clinical team noted gray hyperpigmentation predominantly affecting the face. The patient had received cytarabine and daunorubicin for 10 weeks prior to eltrombopag and sirolimus and mitoxantrone 5 weeks prior to eltrombopag. The patient's hands, nails, sclera, and mucosa were uninvolved. The patient's hyperpigmentation remained stable over the subsequent 8 months during eltrombopag treatment.
A second case was encountered in a 66-yearold female of mixed White, African, and Native American descent with refractory AML. She developed darkening of her skin during treatment with eltrombopag. The patient had received cytarabine and daunorubicin 3 months prior to initiating a clinical trial with eltrombopag. Two months after starting eltrombopag, the patient had a diffuse dusky complexion involving her face, arms, and legs. The patient's pigmentation remained stable 3 months into eltrombopag therapy. The patient, her husband, and the oncology team believed that she was notably darker than before beginning eltrombopag treatment. On comparison with a family photograph, the patient's skin was believed to be darker than baseline according to her dermatologist.
Eltrombopag is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy and for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. It should be noted that the patients received eltrombopag 300 mg daily as part of a clinical trial protocol. The currently recommended dosages of eltrombopag range from 25 mg to 50 mg daily with a maximum daily dosage of 75 mg daily.
